Envafolimab + Regorafenib
NCT06772233
Peking University · Phase 2 · Not yet recruiting · Enrollment 100
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Envafolimab + Regorafenib
Peking University · Phase 2 · Not yet recruiting · Enrollment 100
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.